Caxton Associates LLP Takes Position in Guardant Health, Inc. $GH

Caxton Associates LLP acquired a new position in Guardant Health, Inc. (NASDAQ:GH) during the first quarter, HoldingsChannel.com reports. The fund acquired 8,999 shares of the company’s stock, valued at approximately $831,000.

Other large investors have also recently modified their holdings of the company. Alyeska Investment Group L.P. purchased a new stake in Guardant Health during the third quarter valued at approximately $114,421,000. Price T Rowe Associates Inc. MD grew its holdings in Guardant Health by 33.5% in the fourth quarter. Price T Rowe Associates Inc. MD now owns 5,636,078 shares of the company’s stock worth $575,670,000 after purchasing an additional 1,414,441 shares during the last quarter. Norges Bank acquired a new position in shares of Guardant Health during the fourth quarter worth $128,499,000. Summit Partners Public Asset Management LLC increased its position in shares of Guardant Health by 674.5% during the fourth quarter. Summit Partners Public Asset Management LLC now owns 851,958 shares of the company’s stock worth $87,019,000 after purchasing an additional 741,958 shares in the last quarter. Finally, Westfield Capital Management Co. LP acquired a new position in shares of Guardant Health during the fourth quarter worth $55,073,000. Institutional investors own 92.60% of the company’s stock.

Insider Transactions at Guardant Health

In other Guardant Health news, insider John G. Saia sold 20,000 shares of the business’s stock in a transaction dated Wednesday, May 20th. The stock was sold at an average price of $106.51, for a total transaction of $2,130,200.00. Following the sale, the insider owned 45,950 shares in the company, valued at approximately $4,894,134.50. The trade was a 30.33% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Helmy Eltoukhy sold 100,000 shares of the stock in a transaction dated Friday, June 5th. The shares were sold at an average price of $126.30, for a total value of $12,630,000.00. Following the completion of the transaction, the chief executive officer directly owned 2,012,919 shares in the company, valued at $254,231,669.70. This represents a 4.73% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold 708,565 shares of company stock worth $90,556,597 over the last 90 days. Insiders own 5.60% of the company’s stock.

Guardant Health Stock Performance

NASDAQ:GH opened at $147.33 on Monday. Guardant Health, Inc. has a 12 month low of $40.35 and a 12 month high of $174.08. The firm has a fifty day simple moving average of $139.41 and a 200-day simple moving average of $112.02. The company has a market capitalization of $19.54 billion, a P/E ratio of -43.46 and a beta of 1.59.

Analyst Upgrades and Downgrades

A number of analysts have recently weighed in on GH shares. Morgan Stanley raised their price objective on Guardant Health from $130.00 to $175.00 and gave the stock an “overweight” rating in a research report on Thursday, July 9th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Guardant Health in a research report on Friday, July 17th. Wolfe Research assumed coverage on Guardant Health in a research note on Tuesday, June 2nd. They issued an “outperform” rating and a $150.00 price target for the company. Evercore reissued an “outperform” rating and issued a $200.00 price target on shares of Guardant Health in a report on Monday, July 6th. Finally, Citigroup boosted their price target on Guardant Health from $150.00 to $215.00 and gave the stock a “buy” rating in a research note on Wednesday, July 8th. One research analyst has rated the stock with a Strong Buy rating, twenty-three have issued a Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat, Guardant Health presently has a consensus rating of “Moderate Buy” and a consensus target price of $160.04.

Guardant Health Profile

Guardant Health, Inc is a precision oncology company specializing in blood-based cancer diagnostics. Founded in 2012 and headquartered in Redwood City, California, the company develops non-invasive tests that use circulating tumor DNA (ctDNA) to profile genomic alterations in patients with solid tumors. Guardant Health’s mission is to advance cancer care by providing actionable data to clinicians, pharmaceutical partners and researchers worldwide.

The company’s flagship product, Guardant360, is a next-generation sequencing (NGS) assay designed to detect mutations, copy number variations and select fusions in more than 70 cancer-related genes.